Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$65.39 -2.3%	$56.30	$10.14 ▼ $69.36	$1.70B	1.18	458,029 shs	196,435 shs
NKTR Nektar Therapeutics	$29.28 +1.7%	$24.04	$6.45 ▼ $37.38	$547.35M	0.95	676,553 shs	405,032 shs
WGS GeneDx	$129.19 +2.3%	$97.49	$28.86 ▼ $130.34	$3.63B	2.02	902,400 shs	469,874 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	+4.41%	+8.90%	+8.26%	+195.11%	+420.48%
NKTR Nektar Therapeutics	+6.04%	+7.71%	+15.12%	+174.37%	+41.08%
WGS GeneDx	+3.59%	+4.64%	+58.15%	+80.31%	+254.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.6272 of 5 stars	2.6	3.0	4.6	2.7	1.7	0.0
NKTR Nektar Therapeutics	4.2717 of 5 stars	3.4	4.0	4.2	2.5	2.5	0.0
WGS GeneDx	2.1261 of 5 stars	1.4	2.0	0.0	2.9	4.2	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-1.91% Downside
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	201.68% Upside
WGS GeneDx	2.75	Moderate Buy	$101.63	-21.34% Downside

Current Analyst Ratings Breakdown

Latest NKTR, CDTX, and WGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/4/2025	WGS GeneDx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$110.00 ➝ $120.00
7/30/2025	WGS GeneDx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$78.00 ➝ $95.00
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
7/9/2025	WGS GeneDx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/30/2025	WGS GeneDx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$88.00 ➝ $115.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$1.27M	1,305.74	N/A	N/A	$19.76 per share	3.31
NKTR Nektar Therapeutics	$98.43M	5.66	N/A	N/A	($1.27) per share	-23.06
WGS GeneDx	$305.45M	12.15	$1.05 per share	123.38	$9.65 per share	13.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
NKTR Nektar Therapeutics	-$118.96M	-$8.80	N/A	N/A	N/A	-163.17%	-631.43%	-58.21%	11/6/2025 (Estimated)
WGS GeneDx	-$52.29M	$0.05	2,583.80	61.81	N/A	0.39%	16.51%	9.35%	11/4/2025 (Estimated)

Latest NKTR, CDTX, and WGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	NKTR Nektar Therapeutics	-$3.13	-$2.95	+$0.18	-$2.95	$9.42 million	$11.18 million
7/29/2025	Q2 2025	WGS GeneDx	$0.10	$0.50	+$0.40	$0.36	$86.00 million	$102.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
WGS GeneDx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	16.45	16.45
NKTR Nektar Therapeutics	N/A	2.61	2.61
WGS GeneDx	0.19	2.87	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
NKTR Nektar Therapeutics	75.88%
WGS GeneDx	61.72%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	3.89%
NKTR Nektar Therapeutics	5.25%
WGS GeneDx	29.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
NKTR Nektar Therapeutics	220	19.02 million	18.02 million	Optionable
WGS GeneDx	1,200	28.73 million	20.22 million	Optionable

NKTR, CDTX, and WGS Headlines

Recent News About These Companies

GeneDx (NASDAQ:WGS) Shares Down 5.1% on Insider Selling

August 27 at 2:18 PM | marketbeat.com

GeneDx Holdings Corp. $WGS Shares Acquired by Wellington Management Group LLP

August 27 at 4:11 AM | marketbeat.com

Raymond James Financial Inc. Purchases 68,331 Shares of GeneDx Holdings Corp. $WGS

August 27 at 3:47 AM | marketbeat.com

GeneDx (NASDAQ:WGS) Stock Price Down 5.1% After Insider Selling

August 27 at 2:17 AM | americanbankingnews.com

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

August 26 at 5:09 PM | prnewswire.com

503,733 Shares in GeneDx Holdings Corp. $WGS Purchased by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

GeneDx Holdings Corp. $WGS Shares Sold by Charles Schwab Investment Management Inc.

August 26 at 3:19 AM | marketbeat.com

WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

August 25 at 4:53 PM | globenewswire.com

American Century Companies Inc. Makes New Investment in GeneDx Holdings Corp. $WGS

August 25 at 3:55 AM | marketbeat.com

Vanguard Group Inc. Buys 25,116 Shares of GeneDx Holdings Corp. $WGS

August 25 at 3:14 AM | marketbeat.com

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

August 24 at 9:10 AM | markets.businessinsider.com

GeneDx Holdings Corp. $WGS Shares Purchased by Swiss National Bank

August 24 at 3:30 AM | marketbeat.com

GeneDx Holdings Corp. Stock (WGS) Opinions on 52-Week High and Q2 Earnings

August 23, 2025 | quiverquant.comQ

GeneDx (NASDAQ:WGS) Director Sells $60,450,000.00 in Stock

August 23, 2025 | insidertrades.com

GeneDx Holdings Corp. $WGS Shares Purchased by Algert Global LLC

August 22, 2025 | marketbeat.com

197,912 Shares in GeneDx Holdings Corp. $WGS Acquired by Nuveen LLC

August 22, 2025 | marketbeat.com

WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

August 21, 2025 | globenewswire.com

GeneDx (NASDAQ:WGS) Sets New 1-Year High - Here's What Happened

August 21, 2025 | marketbeat.com

Russell Investments Group Ltd. Raises Holdings in GeneDx Holdings Corp. $WGS

August 21, 2025 | marketbeat.com

Invesco Ltd. Acquires 134,228 Shares of GeneDx Holdings Corp. $WGS

August 20, 2025 | marketbeat.com

Cathie Wood’s ARK Investment buys 170K shares of GeneDx today

August 19, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, CDTX, and WGS Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$65.39 -1.57 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$65.72 +0.33 (+0.51%)

As of 06:25 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Nektar Therapeutics NASDAQ:NKTR

$29.28 +0.50 (+1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$29.08 -0.20 (-0.67%)

As of 07:45 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

GeneDx NASDAQ:WGS

$129.19 +2.94 (+2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$128.26 -0.94 (-0.72%)

As of 07:58 PM Eastern

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time